83 FR 60879 - National Cancer Institute; Notice of Closed Meetings
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 83, Issue 228 (November 27, 2018)
National Institutes of Health
Federal Register Volume 83, Issue 228 (November 27, 2018)
| Page Range | 60879-60880 | |
| FR Document | 2018-25791 |
[Federal Register Volume 83, Number 228 (Tuesday, November 27, 2018)] [Notices] [Pages 60879-60880] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-25791] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI SPORE I (P50) Review. Date: January 29-30, 2019. Time: 8:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington/Rockville Hotel, 1750 Rockville Pike, Rockville, MD 20850. [[Page 60880]] Contact Person: Majed M. Hamawy, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W120, Bethesda, MD 20892-9750, 240-276-6457, [email protected]. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI SPORE III (P50) Review. Date: January 31-February 1, 2019. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852. Contact Person: Paul Carins, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W244, Bethesda, MD 20892-9750, 240-276-5415, [email protected]. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Program Project II (P01). Date: February 6-7, 2019. Time: 8:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Washington/Rockville Hotel, 1750 Rockville Pike, Rockville, MD 20852. Contact Person: Mukesh Kumar, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W618, Bethesda, MD 20892-9750, 240-276-6611, [email protected]. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Program Project III (P01) Review. Date: February 7-8, 2019. Time: 8:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852. Contact Person: Sanita Bharti, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W122, Bethesda, MD 20892-9750, 240-276-5909, [email protected]. Name of Committee: National Cancer Institute Initial Review Group; NCI Program Project V (P01). Date: February 13-14, 2019. Time: 8:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878. Contact Person: Adriana Stoica, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W234, Bethesda, MD 20892-9750, 240-276-6368, [email protected]. Name of Committee: National Cancer Institute Special Emphasis Panel; Innovative Molecular Analysis Technologies. Date: February 13-14, 2019. Time: 4:00 p.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852. Contact Person: Jun Fang, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W634, Bethesda, MD 20892-9750, 240-276-5460, [email protected]. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Program Project IV (P01) Review. Date: February 14-15, 2019. Time: 4:00 p.m. to 2:30 p.m. Agenda: To review and evaluate grant applications. Place: Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878. Contact Person: Robert E. Bird, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W110, Bethesda, MD 20892-9750, 240-276-6344, [email protected]. Name of Committee: National Cancer Institute Special Emphasis Panel; NCORP Minority/Underserved Community Sites (UGIClinical Trial Required). Date: February 26-27, 2019. Time: 5:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878. Contact Person: Scott Chen, Ph.D., Scientific Review Officer, Special Review Branch Division of Extramural Activities National Cancer Institute, NIH 9609 Medical Center Drive, Room 7W526, Bethesda, MD 20892-9750, 240-276-6038, [email protected]. Name of Committee: National Cancer Institute Initial Review Group; Subcommittee J--Career Development. Date: February 28-March 1, 2019. Time: 4:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852. Contact Person: Tushar Deb, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W624, Bethesda, MD 20892-9750 240-276-6132 [email protected]. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: November 20, 2018. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018-25791 Filed 11-26-18; 8:45 am] BILLING CODE 4140-01-P
![Federal Register / Vol. 83, No. 228 / Tuesday, November 27, 2018 / Notices 60879
Place: National Institutes of Health, 5601 with the Acquired Immunodeficiency • Increase in melting temperature (10
Fishers Lane, Rockville, MD 20892 Syndrome (AIDS) pandemic. degrees over BG505 SOSIP).
(Telephone Conference Call). One approach researchers have taken Development Stage: In vivo testing
Contact Person: Frank S. De Silva, Ph.D., to elicit broadly neutralizing antibodies (rodents).
Scientific Review Officer, Scientific Review
against HIV–1 is to stabilize the Inventors: Peter Kwong (NIAID), John
Program, Division of Extramural Activities,
Room #3E72A, National Institutes of Health/ structurally flexible HIV–1 envelope Mascola (NIAID), Gwo-Yu Chuang
NIAID, 5601 Fishers Lane, MSC 9823, (Env) trimer. Researchers stabilized the (NIAID), Cheng Cheng (NIAID), Hui
Rockville, MD 20892–9823, (240) 669–5023, Env trimer in a conformation that Geng (NIAID), Yongping Yang (NIAID)
fdesilva@niaid.nih.gov. displays predominantly broadly and Jeffrey C. Boyington (NIAID).
(Catalogue of Federal Domestic Assistance neutralizing epitopes and few non- Intellectual Property: HHS Reference
Program Nos. 93.855, Allergy, Immunology, neutralizing epitopes. Currently, BG505 Number E–240–2017 includes U.S.
and Transplantation Research; 93.856, DS–SOSIP is a leading vaccine Provisional Patent Application Number
Microbiology and Infectious Diseases candidate with the desired 62/579,973 filed 10/16/2017.
Research, National Institutes of Health, HHS) Related Intellectual Property: HHS
conformation and antigenicity.
Dated: November 20, 2018. Ideally, to be useful as a vaccine, such Reference Number E–187–2014 includes
Natasha M. Copeland, a conformationally fixed Env U.S. Provisional Patent Application
Program Analyst, Office of Federal Advisory immunogen should have high Number 62/046,059 filed 9/4/2014, U.S.
Committee Policy. thermostability and should remain in Provisional Patent Application Number
[FR Doc. 2018–25789 Filed 11–26–18; 8:45 am] the desired antigenic state, even in the 62/136,480 filed 3/21/2015, PCT
BILLING CODE 4140–01–P presence of CD4, a glycoprotein found Application No. PCT/US2015/048729
on the surface of immune cells. filed 9/4/2015, US Patent Application
Researchers at the Vaccine Research 15/508,885 filed 3/3/2017, EP Patent
DEPARTMENT OF HEALTH AND Center (VRC) of the National Institute of Application Number 15766697.5 filed
HUMAN SERVICES Allergy and Infectious Diseases (NIAID) 3/29/2017.
undertook efforts to improve the Licensing Contact: Barry Buchbinder,
National Institutes of Health properties of BG505 DS–SOSIP for use Ph.D., 240–627–3678;
as a vaccine. The VRC researchers barry.buchbinder@nih.gov.
Government-Owned Inventions; introduced three additional mutations Dated: November 14, 2018.
Availability for Licensing to further stabilize BG505 DS–SOSIP in Suzanne M. Frisbie,
AGENCY: National Institutes of Health, the vaccine-preferred prefusion-closed Deputy Director, Technology Transfer and
HHS. conformation and refer to the Intellectual Property Office, National Institute
ACTION: Notice. engineered BG505 DS–SOSIP as BG505 of Allergy and Infectious Diseases.
DS–SOSIP.3mut. Experiments showed [FR Doc. 2018–25787 Filed 11–26–18; 8:45 am]
SUMMARY: The invention listed below is that these modifications conferred BILLING CODE 4140–01–P
owned by an agency of the U.S. improved thermostability that will
Government and is available for allow easier transport and storage of
licensing to achieve expeditious BG505 DS–SOSIP.3mut compared to DEPARTMENT OF HEALTH AND
commercialization of results of BG505 DS–SOSIP. In addition, BG505 HUMAN SERVICES
federally-funded research and DS–SOSIP.3mut has lower antigenicity
development. Foreign patent toward non/weak neutralizing National Institutes of Health
applications are filed on selected antibodies compared to BG505 DS–
inventions to extend market coverage SOSIP, which suggests that it could National Cancer Institute; Notice of
for companies and may also be available potentially elicit higher neutralization Closed Meetings
for licensing. titer by targeting only broadly Pursuant to section 10(d) of the
FOR FURTHER INFORMATION CONTACT: neutralizing antibodies. With improved Federal Advisory Committee Act, as
Barry Buchbinder, Ph.D., 240–627– antigenicity and stability, this version amended, notice is hereby given of the
3678; barry.buchbinder@nih.gov. may have utility as an HIV–1 following meetings.
Licensing information and copies of the immunogen or in other antigen-specific The meetings will be closed to the
U.S. patent application listed below contexts, such as for use with B-cell public in accordance with the
may be obtained by communicating probes. provisions set forth in sections
with the indicated licensing contact at This technology is available for 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
the Technology Transfer and licensing for commercial development as amended. The grant applications and
Intellectual Property Office, National in accordance with 35 U.S.C. 209 and 37 the discussions could disclose
Institute of Allergy and Infectious CFR part 404. confidential trade secrets or commercial
Diseases, 5601 Fishers Lane, Rockville, Potential Commercial Applications property such as patentable material,
MD 20852; tel. 301–496–2644. A signed and personal information concerning
Confidential Disclosure Agreement will • Vaccine—to elicit potent individuals associated with grant
be required to receive copies of neutralizing antibodies against the HIV– applications, the disclosure of which
unpublished patent applications. 1 Env glycoprotein. would constitute a clearly unwarranted
SUPPLEMENTARY INFORMATION:
• Probes—to identify broad and invasion of personal privacy.
Technology description follows. potent HIV–1-neutralizing antibodies.
Name of Committee: National Cancer
amozie on DSK3GDR082PROD with NOTICES1
Recombinant HIV–1 Envelope Proteins Competitive Advantages Institute Special Emphasis Panel; NCI SPORE
I (P50) Review.
and Their Use Compared to previous engineered Env Date: January 29–30, 2019.
trimer versions: Time: 8:00 a.m. to 12:00 p.m.
Description of Technology • 300-fold reduction in CD4-binding Agenda: To review and evaluate grant
An effective human affinity. applications.
immunodeficiency virus type 1 (HIV–1) • Reduced binding affinity to Place: Hilton Washington/Rockville Hotel,
vaccine has long been sought to contend ineffective HIV–1 antibodies. 1750 Rockville Pike, Rockville, MD 20850.
VerDate Sep<11>2014 17:45 Nov 26, 2018 Jkt 247001 PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 E:\FR\FM\27NON1.SGM 27NON1](https://thefederalregister.org/doc/83_FR_61107/page/1.svg)
![60880 Federal Register / Vol. 83, No. 228 / Tuesday, November 27, 2018 / Notices
Contact Person: Majed M. Hamawy, Ph.D., Name of Committee: National Cancer Research; 93.397, Cancer Centers Support;
Scientific Review Officer, Research Program Institute Special Emphasis Panel; Innovative 93.398, Cancer Research Manpower; 93.399,
Review Branch, Division of Extramural Molecular Analysis Technologies. Cancer Control, National Institutes of Health,
Activities, National Cancer Institute, NIH, Date: February 13–14, 2019. HHS)
9609 Medical Center Drive, Room 7W120, Time: 4:00 p.m. to 8:00 p.m. Dated: November 20, 2018.
Bethesda, MD 20892–9750, 240–276–6457, Agenda: To review and evaluate grant
applications. Melanie J. Pantoja,
mh101v@nih.gov.
Place: Bethesda North Marriott Hotel & Program Analyst, Office of Federal Advisory
Name of Committee: National Cancer Committee Policy.
Conference Center, 5701 Marinelli Road,
Institute Special Emphasis Panel; NCI SPORE
North Bethesda, MD 20852. [FR Doc. 2018–25791 Filed 11–26–18; 8:45 am]
III (P50) Review.
Contact Person: Jun Fang, Ph.D., Scientific
Date: January 31–February 1, 2019. BILLING CODE 4140–01–P
Review Officer, Research Technology and
Time: 8:00 a.m. to 5:00 p.m. Contract Review Branch, Division of
Agenda: To review and evaluate grant Extramural Activities, National Cancer
applications. Institute, NIH, 9609 Medical Center Drive,
DEPARTMENT OF HEALTH AND
Place: Bethesda North Marriott Hotel & Room 7W634, Bethesda, MD 20892–9750, HUMAN SERVICES
Conference Center, 5701 Marinelli Road, 240–276–5460, jfang@mail.nih.gov.
North Bethesda, MD 20852. National Institutes of Health
Contact Person: Paul Carins, Ph.D., Name of Committee: National Cancer
Scientific Review Officer, Research Program Institute Special Emphasis Panel; NCI National Institute of Diabetes and
Review Branch, Division of Extramural Program Project IV (P01) Review.
Date: February 14–15, 2019.
Digestive and Kidney Diseases; Notice
Activities, National Cancer Institute, NIH, of Closed Meetings
Time: 4:00 p.m. to 2:30 p.m.
9609 Medical Center Drive, Room 7W244,
Agenda: To review and evaluate grant Pursuant to section 10(d) of the
Bethesda, MD 20892–9750, 240–276–5415,
applications.
paul.cairns@nih.gov. Federal Advisory Committee Act, as
Place: Gaithersburg Marriott
Name of Committee: National Cancer Washingtonian Center, 9751 Washingtonian amended, notice is hereby given of the
Institute Special Emphasis Panel; NCI Boulevard, Gaithersburg, MD 20878. following meetings.
Program Project II (P01). Contact Person: Robert E. Bird, Ph.D., The meetings will be closed to the
Date: February 6–7, 2019. Scientific Review Officer, Research Program public in accordance with the
Time: 8:00 a.m. to 2:00 p.m. Review Branch, Division of Extramural provisions set forth in sections
Agenda: To review and evaluate grant Activities, National Cancer Institute, NIH, 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
applications. 9609 Medical Center Drive, Room 7W110, as amended. The grant applications and
Place: Hilton Washington/Rockville Hotel, Bethesda, MD 20892–9750, 240–276–6344, the discussions could disclose
1750 Rockville Pike, Rockville, MD 20852. birdr@mail.nih.gov.
Contact Person: Mukesh Kumar, Ph.D., confidential trade secrets or commercial
Name of Committee: National Cancer property such as patentable material,
Scientific Review Officer, Research Program Institute Special Emphasis Panel; NCORP
Review Branch, Division of Extramural and personal information concerning
Minority/Underserved Community Sites
Activities, National Cancer Institute, NIH, individuals associated with the grant
(UGIClinical Trial Required).
9609 Medical Center Drive, Room 7W618, Date: February 26–27, 2019. applications, the disclosure of which
Bethesda, MD 20892–9750, 240–276–6611, Time: 5:00 p.m. to 5:00 p.m. would constitute a clearly unwarranted
mukesh.kumar3@nih.gov. Agenda: To review and evaluate grant invasion of personal privacy.
Name of Committee: National Cancer applications. Name of Committee: National Institute of
Institute Special Emphasis Panel; NCI Place: Gaithersburg Marriott Diabetes and Digestive and Kidney Diseases
Program Project III (P01) Review. Washingtonian Center, 9751 Washingtonian Special Emphasis Panel; Treating Diabetes
Date: February 7–8, 2019. Boulevard, Gaithersburg, MD 20878. Distress to Improve Glycemic Outcomes in
Time: 8:00 a.m. to 1:00 p.m. Contact Person: Scott Chen, Ph.D., Type1 Diabetes.
Agenda: To review and evaluate grant Scientific Review Officer, Special Review Date: December 17, 2018.
applications. Branch Division of Extramural Activities Time: 12:00 p.m. to 4:00 p.m.
Place: Bethesda North Marriott Hotel & National Cancer Institute, NIH 9609 Medical Agenda: To review and evaluate grant
Conference Center, 5701 Marinelli Road, Center Drive, Room 7W526, Bethesda, MD applications.
North Bethesda, MD 20852. 20892–9750, 240–276–6038, chensc@ Place: National Institutes of Health, Two
Contact Person: Sanita Bharti, Ph.D., mail.nih.gov. Democracy Plaza, 6707 Democracy
Scientific Review Officer, Research Program Name of Committee: National Cancer Boulevard, Bethesda, MD 20892 (Telephone
Review Branch, Division of Extramural Institute Initial Review Group; Subcommittee Conference Call).
Activities, National Cancer Institute, NIH, J—Career Development. Contact Person: Paul A. Rushing, Ph.D.,
9609 Medical Center Drive, Room 7W122, Date: February 28–March 1, 2019. Scientific Review Officer, Review Branch,
Bethesda, MD 20892–9750, 240–276–5909, Time: 4:00 p.m. to 4:00 p.m. DEA, NIDDK, National Institutes of Health,
sanitab@mail.nih.gov. Agenda: To review and evaluate grant Room 7345, 6707 Democracy Boulevard,
Name of Committee: National Cancer applications. Bethesda, MD 20892–5452, (301) 594–8895,
Institute Initial Review Group; NCI Program Place: Bethesda North Marriott Hotel & rushingp@extra.niddk.nih.gov.
Project V (P01). Conference Center, 5701 Marinelli Road, Name of Committee: National Institute of
Date: February 13–14, 2019. North Bethesda, MD 20852. Diabetes and Digestive and Kidney Diseases
Time: 8:00 a.m. to 4:00 p.m. Contact Person: Tushar Deb, Ph.D., Special Emphasis Panel; NIDDK Crohn’s
Agenda: To review and evaluate grant Scientific Review Officer, Resources and Disease Ancillary Studies.
applications. Training Review Branch, Division of Date: December 20, 2018.
Place: Gaithersburg Marriott Extramural Activities, National Cancer Time: 1:00 p.m. to 2:30 p.m.
Washingtonian Center, 9751 Washingtonian Institute, NIH, 9609 Medical Center Drive, Agenda: To review and evaluate grant
amozie on DSK3GDR082PROD with NOTICES1
Boulevard, Gaithersburg, MD 20878. Room 7W624, Bethesda, MD 20892–9750 applications.
Contact Person: Adriana Stoica, Ph.D., 240–276–6132 tushar.deb@nih.gov. Place: National Institutes of Health, Two
Scientific Review Officer, Resources and (Catalogue of Federal Domestic Assistance Democracy Plaza, 6707 Democracy
Training Review Branch, Division of Program Nos. 93.392, Cancer Construction; Boulevard, Bethesda, MD 20892 (Telephone
Extramural Activities, National Cancer 93.393, Cancer Cause and Prevention Conference Call).
Institute, NIH, 9609 Medical Center Drive, Research; 93.394, Cancer Detection and Contact Person: Elena Sanovich, Ph.D.,
Room 7W234, Bethesda, MD 20892–9750, Diagnosis Research; 93.395, Cancer Scientific Review Officer, Review Branch,
240–276–6368, Stoicaa2@mail.nih.gov. Treatment Research; 93.396, Cancer Biology DEA, NIDDK, National Institutes of Health,
VerDate Sep<11>2014 17:45 Nov 26, 2018 Jkt 247001 PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 E:\FR\FM\27NON1.SGM 27NON1](https://thefederalregister.org/doc/83_FR_61107/page/2.svg)
Document Created: 2018-11-27 01:25:02
Document Modified: 2018-11-27 01:25:02
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | January 29-30, 2019. | |
| FR Citation | 83 FR 60879 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR